Huntington Disease Clinical Trial
Official title:
N-homocysteinylated Huntingtin in Huntington's Disease
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: 1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), 2. symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin) 3. human control cell lines, unmutated Huntingtin
Prospective inclusions of 32 subjects with 24 symptomatic HD patients and 8 presymptomatic HD patients.Rationale: This is a pilot study in humans. Over a period of 2 years, the potential recruitment should make it possible to include 32 patients This number will make it possible to calculate the overall variability of the dosage and to have statistics of position and dispersion in the 2 subgroups identified. Controls: Eight standardized cell lines from human fibroblasts ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
Not yet recruiting |
NCT05360082 -
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
|
||
Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A |